Inventor · disambiguated record
David Altreuter
Also filed as: ALTREUTER DAVID · ALTREUTER DAVID H
11 granted patents·30 pending applications·401 citations·filing 2002–2025
92Inventor score
Files withLYNDRA THERAPEUTICS INC11ACUSPHERE INC9SELECTA BIOSCIENCES INC7CHICKERING DONALD E III3ALTREUTER DAVID H2
Top patents by PatentIndex Score
41 records- 0196US10039822B2Method for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responsesSELECTA BIOSCIENCES INC·Filed 2015·Granted Aug 7, 2018·31 cites·24 claims
- 0296US7919119B2Porous drug matrices and methods of manufacture thereofACUSPHERE INC·Filed 2002·Granted Apr 5, 2011·60 cites·7 claims
- 0396US6962006B2Methods and apparatus for making particles using spray dryer and in-line jet millACUSPHERE INC·Filed 2002·Granted Nov 8, 2005·91 cites·53 claims
- 0496US6921458B2Methods and apparatus for making particles using spray dryer and in-line jet millACUSPHERE INC·Filed 2004·Granted Jul 26, 2005·69 cites·17 claims
- 0596US6918991B2Methods and apparatus for making particles using spray dryer and in-line jet millACUSPHERE INC·Filed 2004·Granted Jul 19, 2005·95 cites·24 claims
- 0695US11235057B2Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responsesSELECTA BIOSCIENCES INC·Filed 2018·Granted Feb 1, 2022·8 cites·17 claims
- 0791US6800297B2Porous COX-2 inhibitor matrices and methods of manufacture thereofACUSPHERE INC·Filed 2003·Granted Oct 5, 2004·36 cites·25 claims
- 0884US12023406B2Gastric residence systems with release rate-modulating filmsLYNDRA THERAPEUTICS INC·Filed 2018·Granted Jul 2, 2024·2 cites·57 claims
- 0981US10933129B2Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responsesALTREUTER DAVID H·Filed 2012·Granted Mar 2, 2021·6 cites·19 claims
- 1081US8821938B2Porous drug matrices and methods of manufacture thereofSTRAUB JULIE·Filed 2011·Granted Sep 2, 2014·3 cites·18 claims
- 1179US2022354947A1Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responsesSELECTA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1278US2025152561A1Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated stateCARTESIAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1374US2024382418A1Gastric residence systems with release rate-modulating filmsLYNDRA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1471US2025188450A1Universal suppressor trnas and uses thereofHC BIOSCIENCE INC·Filed 2024·Application pending·0 cites
- 1570US2025163409A1Modified transfer rna with improved activityHC BIOSCIENCE INC·Filed 2024·Application pending·0 cites
- 1667US2023139671A1Osmotic mediated release synthetic nanocarriersSELECTA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 1766US2005058710A1Porous drug matrices and methods of manufacture thereofACUSPHERE INC·Filed 2004·Application pending·0 cites
- 1865US2025332111A1Capsules and capsule coatings for gastric residence dosage formsLYNDRA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1963US2005079138A1Methods for making pharmaceutical formulations comprising microparticles with improved dispersibility, suspendability or wettabilityFiled 2004·Application pending·0 cites
- 2062US2005209099A1Methods and apparatus for making particles using spray dryer and in-line jet millCHICKERING DONALD E III·Filed 2005·Application pending·0 cites
- 2162US2013059009A1Compositions and methods for producing antigen-specific induced tolerogenic dendritic cells with synthetic nanocarriersKISHIMOTO TAKASHI KEI·Filed 2012·Application pending·0 cites
- 2262US2006093678A1Methods for making pharmaceutical formulations comprising deagglomerated microparticlesCHICKERING DONALD E III·Filed 2005·Application pending·0 cites
- 2362US2006093677A1Methods for making pharmaceutical formulations comprising deagglomerated microparticlesCHICKERING DONALD E III·Filed 2005·Application pending·0 cites
- 2458US12447130B2Capsules and capsule coatings for gastric residence dosage formsLYNDRA THERAPEUTICS INC·Filed 2020·Granted Oct 21, 2025·0 cites·20 claims
- 2558US2004121003A1Methods for making pharmaceutical formulations comprising deagglomerated microparticlesACUSPHERE INC·Filed 2002·Application pending·0 cites
- 2658US2005048116A1Porous drug matrices and methods of manufacture thereofFiled 2004·Application pending·0 cites
- 2755US2024252483A1Gastric residence systems comprising buprenorphine and naloxoneLYNDRA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2855US2024335400A1Gastric residence systems comprising methadoneLYNDRA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2954US2007148211A1Processes for making particle-based pharmaceutical formulations for oral administrationACUSPHERE INC·Filed 2006·Application pending·0 cites
- 3054US2007178165A1Processes for making particle-based pharmaceutical formulations for parenteral administrationACUSPHERE INC·Filed 2006·Application pending·0 cites
- 3153US2024390270A1Gastric residence systems for administration of risperidoneLYNDRA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3249US2022387312A1Gastric residence systems having arms with controlled stiffness for improved gastric residenceLYNDRA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3347US2022387311A1Gastric residence systems for administration of active agentsLYNDRA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3447US2022387310A1Formulations for release-rate modulating films for gastric residence systemsLYNDRA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3546US2021196627A1Systems for enteric delivery of therapeutic agentsLYNDRA INC·Filed 2019·Application pending·0 cites
- 3645US2016128986A1Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalogSELECTA BIOSCIENCES INC·Filed 2015·Application pending·0 cites
- 3745US2016128987A1Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated stateSELECTA BIOSCIENCES INC·Filed 2015·Application pending·0 cites
- 3842US2023190941A1Polymeric linkers for a gastric residence systemLYNDRA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3940US2012244222A1Osmotic mediated release synthetic nanocarriersALTREUTER DAVID H·Filed 2012·Application pending·0 cites
- 4038US2012070493A1Targeted multi-epitope dosage forms for induction of an immune response to antigensFRASER CHRISTOPHER·Filed 2011·Application pending·0 cites
- 4136US2011110965A1Compositions that induce t cell helpSELECTA BIOSCIENCES INC·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →